Literature DB >> 6113147

Induction of drug metabolizing enzymes by sulfinpyrazone.

E Walter, C Staiger, J de Vries, R Zimmermann, E Weber.   

Abstract

A previous interaction study of sulfinpyrazone (Anturano) suggested that it induced microsomal drug metabolizing enzymes in the liver. To verify this finding the effect of sulfinpyrazone 800 mg per day for four weeks was investigated in ten healthy volunteers. Both the therapeutic actions of sulfinpyrazone, the uricosuric and the antiaggregating effects, were demonstrated (p less than 0.05). The influence on the microsomal drug metabolizing system in the liver was demonstrated by an increase in serum-gamma-glutamyl transpeptidase from 15.1 to 23.3 U/l (p greater than 0.05), a significant increase in the urinary excretion of d-glucaric acid (29.6 to 77.9 microMol/24 h, p less than 0.05) and an increase in antipyrine clearance from 50.3 ml/min to 83.9 ml/min (p less than 0.05). The possibility of enhancement of drug metabolism during treatment with sulfinpyrazone in combination with other drugs should be kept in mind.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6113147     DOI: 10.1007/bf00544586

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671.

Authors:  J J BURNS; T F YU; A RITTERBAND; J M PEREL; A B GUTMAN; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1957-03       Impact factor: 4.030

2.  Urinary D-glucaric acid excretion and plasma antipyrine kinetics during enzyme induction.

Authors:  M Davis; C J Simmons; B Dordoni; R Williams
Journal:  Br J Clin Pharmacol       Date:  1974-06       Impact factor: 4.335

3.  Hepatic enzyme induction and its relationship to urinary D-glucaric acid excretion in man.

Authors:  D S Lecamwasam
Journal:  Br J Clin Pharmacol       Date:  1975-12       Impact factor: 4.335

4.  Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers.

Authors:  S Lindgren; P Collste; B Norlander; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

5.  Plasma gamma-glutamyl transpeptidase elevation in patients receiving enzyme-inducing drugs.

Authors:  S B Rosalki; D Tarlow; D Rau
Journal:  Lancet       Date:  1971-08-14       Impact factor: 79.321

6.  Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man.

Authors:  J Hunter; J D Maxwell; M Carrella; D A Stewart; R Williams
Journal:  Lancet       Date:  1971-03-20       Impact factor: 79.321

7.  A kinetic photometric method for serum gamma-glutamyl transpeptidase.

Authors:  G Szasz
Journal:  Clin Chem       Date:  1969-02       Impact factor: 8.327

8.  The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis.

Authors:  A Kaegi; G F Pineo; A Shimizu; H Trivedi; J Hirsh; M Gent
Journal:  Circulation       Date:  1975-09       Impact factor: 29.690

9.  Prediction of drug oxidation rates in man: lack of correlation with serum gamma-glutamyl transpeptidase and urinary excretion of D-glucaric acid and 6 beta-hydroxycortisol.

Authors:  S E Smith; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

10.  A randomized trial of aspirin and sulfinpyrazone in threatened stroke.

Authors: 
Journal:  N Engl J Med       Date:  1978-07-13       Impact factor: 91.245

View more
  11 in total

1.  Antipyrine clearance during occupational exposure to styrene.

Authors:  M Døssing
Journal:  Br J Ind Med       Date:  1983-05

2.  Plasma levels and pharmacokinetics of sulphinpyrazone in renal impairment during chronic treatment: a case report.

Authors:  J Godbillon; J P Schoeller; S Gauron; G Gosset; J P Fillastre
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

3.  Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state.

Authors:  B Rosenkranz; C Fischer; P Jakobsen; A Kirstein Pedersen; J C Frölich
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone.

Authors:  A K Pedersen; P Jakobsen; J P Kampmann; J M Hansen
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

5.  The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination.

Authors:  J O Miners; T Foenander; S Wanwimolruk; A S Gallus; D J Birkett
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years.

Authors:  E Walter; C Staiger; J de Vries; E Weber; W Bitzer; M Degott; K Jüngling
Journal:  Klin Wochenschr       Date:  1982-11-15

7.  Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects.

Authors:  Helene Sabia; Gangadhar Sunkara; Monica Ligueros-Saylan; Yibin Wang; Harold Smith; James McLeod; Pratapa Prasad
Journal:  Eur J Clin Pharmacol       Date:  2004-06-09       Impact factor: 2.953

8.  Effect of single and multiple doses of sulphinpyrazone on antipyrine metabolism and urinary excretion of 6-beta-hydroxycortisol.

Authors:  C Staiger; F Schlicht; E Walter; U Gundert-Remy; R Hildebrandt; J de Vries; N S Wang; J Harenberg; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction.

Authors:  D J Birkett; J O Miners; J Attwood
Journal:  Br J Clin Pharmacol       Date:  1983-05       Impact factor: 4.335

10.  Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.

Authors:  F Schlicht; C Staiger; J de Vries; U Gundert-Remy; R Hildebrandt; J Harenberg; N S Wang; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.